Raptor Pharmaceutical Corp. Insider Sells $212,550 in Stock (RPTP)
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Insider Thomas E. Daley sold 15,000 shares of Raptor Pharmaceutical Corp. stock in a transaction that occurred on Thursday, January 9th. The shares were sold at an average price of $14.17, for a total transaction of $212,550.00. Following the completion of the transaction, the insider now directly owns 39,906 shares of the company’s stock, valued at approximately $565,468. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded down 1.69% on Monday, hitting $14.56. 993,697 shares of the company’s stock traded hands. Raptor Pharmaceutical Corp. has a 52 week low of $4.71 and a 52 week high of $15.39. The stock has a 50-day moving average of $13.68 and a 200-day moving average of $12.81. The company’s market cap is $892.4 million.
A number of research firms have recently commented on RPTP. Analysts at Ladenburg Thalmann raised their price target on shares of Raptor Pharmaceutical Corp. from $12.00 to $15.50 in a research note to investors on Monday, November 11th. They now have a “buy” rating on the stock. Separately, analysts at Janney Montgomery Scott raised their price target on shares of Raptor Pharmaceutical Corp. from $13.00 to $17.00 in a research note to investors on Monday, November 11th. They now have a “buy” rating on the stock. Finally, analysts at FBR & Co. initiated coverage on shares of Raptor Pharmaceutical Corp. in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $14.93.
Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.